Clinical trials: PCD
Nasopharyngeal Cancer
Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT
Nasopharyngeal carcinoma is biologically different from traditional head and neck squamous cell carcinoma. The mainstay treatment for locally advanced nasopharyngeal carcinoma is cisplatin-based concurrent chemoradiation.
- Trial name
- NCT05628922
- Testing
- Toripalimab, Induction chemotherapy and concurrent chemoradiation
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Fudan University
Cardiomyocyte Apoptosis
Cardiomyocyte Apoptosis Following Antegrade and Retrograde Cardioplegia
Retrograde cardioplegia during heart surgery is associated with inadequate myocardial protection. In experimental animal study retrograde cardioplegia induces more cardiomyocyte apoptosis when compared to antegrade cardioplegia.
- Trial name
- NCT01185912
- Testing
- Ventricle muscle tissue samples
- Where
- Finland
- Volunteers
- 20 people
- Sponsor
- Turku University Hospital
Neoplasms, Carcinoma, Non-Small-Cell Lung
Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)
This is an open-label, non-randomized, Phase I study of epacadostat (INCB024360) alone and in combination with pembrolizumab with chemotherapy and pembrolizumab without chemotherapy in participants with advanced solid tumors.
- Trial name
- NCT02862457
- Testing
- Epacadostat 25 mg, Epacadostat 100 mg, pembrolizumab 200 mg
- Volunteers
- 34 people
- Sponsor
- Merck Sharp & Dohme LLC
Kartagener Syndrome, Cystic Fibrosis
Rare Genetic Disorders of the Breathing Airways
Mucociliary clearance, in which mucus secretions are cleared from the breathing airways, is the primary defense mechanism for the lungs.
- Conditions
- Kartagener Syndrome, Cystic Fibrosis, Pseudohypoaldosteronism, Primary Ciliary Dyskinesia
- Trial name
- NCT00323167
- Where
- 9 sites in United States, Canada
- Volunteers
- 367 people
- Sponsor
- University of North Carolina, Chapel Hill
Renal Cell Carcinoma
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
The purpose of this study is to assess the safety and efficacy of monotherapy pembrolizumab (MK-3475) in participants with renal cell carcinoma (RCC).
- Trial name
- NCT02853344
- Testing
- Pembrolizumab
- Volunteers
- 275 people
- Sponsor
- Merck Sharp & Dohme LLC
Oral Cancer, VEGFR2 Inhibitor
Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma
In patients with locally advanced oral squamous cell carcinoma (OSCC), due to the large tumor burden and neck lymph node metastasis, comprehensive treatment is recommended, including surgery, radiotherapy, chemotherapy and…
- Conditions
- Oral Cancer, VEGFR2 Inhibitor, Programmed Cell Death 1 Inhibitor, Inductive Therapy
- Trial name
- NCT04393506
- Testing
- Camrelizumab, Apatinib, Radical surgery
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Hepatocellular Carcinoma
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)
This is a efficacy and safety study of pembrolizumab (MK-3475, KEYTRUDA®) as monotherapy in participants with hepatocellular carcinoma (HCC) in two cohorts: participants with advanced HCC and with no curative option after disease…
- Trial name
- NCT02702414
- Testing
- Pembrolizumab
- Volunteers
- 156 people
- Sponsor
- Merck Sharp & Dohme LLC
Mitral Valve Regurgitation, Left Atrium Dilatation and Hypertrophy
Pilot Study of Lovaza (Omega 3 Fatty Acids) to Improve Cardiac Antioxidant/Anti-inflammatory Profile Before Cardiac Surgery
In the absence of treatment, severe mitral valve regurgitation (MR) results in left atrium (LA) dilatation and hypertrophy, followed ultimately by left ventricular dysfunction and heart failure.
- Conditions
- Mitral Valve Regurgitation, Left Atrium Dilatation and Hypertrophy, Mitochondrial Dysfunction in the Heart, Cardiomyocyte Apoptosis
- Trial name
- NCT01046604
- Testing
- Lovaza group
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- East Carolina University
Breast Cancer, Postmenopausal
Study of Statin as Neo-Adjuvant Therapy in Postmenopausal Breast Cancer
The purpose of this study is to monitor: Tumor biological alterations following two weeks of neo-adjuvant statin therapy. Effects of statins on tumor proliferation. Functional studies on the mevalonate pathway.
- Trial name
- NCT00816244
- Testing
- Atorvastatin
- Where
- Sweden
- Volunteers
- 50 people
- Sponsor
- Lund University Hospital
Kidney Transplantation, Anemia
Effects of Anemia Correction on Vascular and Monocyte Function in Renal Transplant Recipients
Correction of anaemia in renal transplant recipients by parenteral application of recombinant erythropoietin and if necessary iron will improve large artery function (endothelial function and elasticity), as assessed by…
- Trial name
- NCT00204334
- Testing
- darbopoeitin
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University Hospital Muenster
Sarcopenia
Skeletal Muscle Apoptosis and Physical Performance; Oxidative RNA/DNA Damage and Repair in Aged Human Muscle
The age-related loss of muscle mass and strength, also termed sarcopenia, is a commonly recognized consequence of aging and has been associated with frailty, functional loss, hospitalization, and increased mortality among older…
- Trial name
- NCT01644279
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of Florida
Primary Ciliary Dyskinesia
A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults
The goal of this observational study is to characterize clinical measures and biomarkers of airway disease in adults with primary ciliary dyskinesia (PCD) and in a group of healthy volunteers (HV) to establish normative values.
- Trial name
- NCT05685186
- Testing
- Spirometry, Multiple Breath Washout (MBW), Mucociliary Clearance (MCC)
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- ReCode Therapeutics
Melanoma
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
Substudy 02B is part of a larger research study where researchers are looking for new ways to treat advanced melanoma that has not been treated before. The larger study is the umbrella study.
- Trial name
- NCT04305054
- Testing
- Pembrolizumab, Vibostolimab, Pembrolizumab/Quavonlimab
- Where
- 60 sites in United States, Argentina and 12 more
- Volunteers
- 335 people
- Sponsor
- Merck Sharp & Dohme LLC
Fertilization in Vitro
The Comparison of Granulosa Cell Apoptosis Rates With or Without Luteinizing Hormone Administration in Poor Responders.
In Zeynep Kamil Women and Children's Education and Research Hospital which is a tertiary referral hospital, the investigators perform microdose flare-up gonadotropin-releasing hormone (GNRH) analogue or GNRH antagonist protocol…
- Trial name
- NCT03527823
- Where
- Turkey (Türkiye)
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Sebnem Alanya Tosun
Refractory Metastatic Colorectal Cancer
A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
A Phase 2 Study with Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Participants with Microsatellite Stable Refractory Metastatic Colorectal Cancer
- Trial name
- NCT02860546
- Testing
- TAS-102, nivolumab
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Taiho Oncology, Inc.
Obesity, Weight Loss
Oxidative Stress and L-CBMN Cytome Assay in Obese After 3 Weeks VLCD
Obesity leads to physiological imbalance resulting in hyperglycemia, dyslipidaemia and inflammation and can generate systematic oxidative stress through multiple biochemical mechanisms.
- Conditions
- Obesity, Weight Loss, DNA Damage
- Trial name
- NCT05055154
- Testing
- Very low calorie diet
- Where
- Croatia
- Volunteers
- 26 people
- Sponsor
- Special Hospital for Extended Treatment of Duga Resa
Cystic Fibrosis, Primary Ciliary Dyskinesia
Bacteriological Link Between Upper and Lower Airways in Cystic Fibrosis and Primary Ciliary Dyskinesia
Cytobacteriological examination of sputum and bacteriological sampling in the middle meatus.
- Trial name
- BAVASI (NCT03494894)
- Testing
- Middle meatus aspirations and sputum
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Esophageal Squamous Cell Carcinoma
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for the treatment of participants…
- Trial name
- NCT05319730
- Testing
- Paclitaxel, Irinotecan, Pembrolizumab
- Where
- 58 sites in United States, Brazil and 12 more
- Volunteers
- 230 people
- Sponsor
- Merck Sharp & Dohme LLC
Ischemia-Reperfusion Injury, Myocardial Infarction
Infusion of a Single Dose of Erythropoietin to Prevent Injury in an Ischemia Reperfusion Forearm Model
Rationale: The investigators hypothesize that EPO protects against apoptosis after acute ischemia in man and that it is detectable using the annexin-A5 model.
- Trial name
- IPIIR (NCT00691613)
- Testing
- Epoetin alpha, NaCl
- Where
- Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
Lymphoma
Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma
This is a phase I, open-label, dose-escalation study of CUDC-427 in patients with advanced or refractory solid tumors or lymphoma.
- Trial name
- NCT01908413
- Testing
- CUDC-427
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Curis, Inc.